Twenty thousand transplants: a quarter-century view of Indian organ transplantation

By Caleb Masih Founder & Managing Director, Vyapitus Specialities Private Limited Executive Director, LawCrust Global Consulting Ltd. (a Public Limited Company; CIN U69100MH2023PLC413428)

Twenty-five years in pharmaceutical super-speciality leadership, with a particular focus on nephrology and solid-organ transplantation.

Executive summary

In 2025, India crossed 20,138 organ transplants in a single calendar year for the first time in its history — a 6.5 % rise over 2024 and a more-than-fourfold increase from the 4,990 transplants recorded in 2013.¹²³ The country now ranks third globally in total transplant volume, behind only the United States and China, and remains the world’s largest performer of living-donor transplants.²⁴

I have spent twenty-five years in this therapy area, in senior commercial and clinical-partnership roles across leading Indian super-speciality pharmaceutical companies. I began when the entire national conversation on organ transplantation still centred on the related living donor — a sibling, a parent, occasionally a spouse — and the routine post-transplant medicine chest fit inside three or four molecules. I write this after a year in which our sector performed transplants at a rate India could not have credibly projected a decade ago.

This is not a scientific evidence review. It is a field perspective from someone who has watched the discipline transition from the inside. The 20,138 headline is the culmination of ten structural shifts, all of which happened simultaneously and reinforced one another: who could donate, what we could give them, what it cost, where it could be done, who was pledging, who was talking about it in public, how India is now perceived globally, who is flying in for care, how much internal disease still goes unmet, and what framework must hold the whole thing together going forward. Each is worth naming.

1. The number — and what it means to see it

The National Organ and Tissue Transplant Organisation (NOTTO)‘s 2025 total of 20,138 solid-organ transplants is a real-world outcome of policy, infrastructure, clinical practice and public awareness all inflecting upward at once.² The trajectory:

Growth of this magnitude in a decade is not a marketing slide; it is a genuine capacity expansion. The country still faces a substantial demand-supply gap — of which more in Section 9 — but the direction, and the acceleration, are both correct.

Alongside it: more than five lakh Aadhaar-verified organ-donation pledges have been registered since NOTTO launched its digital pledge portal in 2023.⁴ Pledges are not transplants. But a country that could not, ten years ago, muster fifty thousand pledges is now well past half a million. Cultural friction against organ donation — religious, familial, procedural — is measurably softening. That was not inevitable.

2. The donor journey — from related, to unrelated, to cadaver, to non-match

The single most consequential change I have watched over twenty-five years is who India has been willing (and technically able) to accept as a donor.

Phase one — the related-donor era. For most of the 2000s, an Indian kidney transplant almost always meant a first-degree relative — a parent, a sibling, sometimes a child — donating one kidney to a loved one. The Transplantation of Human Organs Act, 1994 was clear: unrelated donation required Authorisation Committee approval and was, by design, made rare. Clinically this was safe and immunologically manageable; societally it left thousands of patients whose families were too small, too old, or too medically compromised to donate.

Phase two — the unrelated-donor expansion. As Authorisation Committee frameworks matured and clinical outcomes with unrelated donors proved comparable, “unrelated” donation — spouses, in-laws, extended family, altruistic non-relatives under strict scrutiny — became a legitimate and often necessary path. The clinical challenge widened: a wider donor pool meant a wider spectrum of HLA mismatch, which the therapy had to catch up with.

Phase three — the cadaver transition. The word most Indian transplant clinicians have used for the last fifteen years is deceased-donor or cadaveric donation — donation after brainstem death. This is where India’s growth has been most dramatic. Every state has now established (or is establishing) a State Organ and Tissue Transplant Organisation (SOTTO); NOTTO coordinates the national allocation; hospitals have Transplant Coordinators whose full-time job is to counsel bereaved families. In 2024, India recorded approximately 1,128 deceased donors — still a fraction of what the population needs, but an order of magnitude beyond where the country stood in 2010.²

Phase four — non-match donors, ABO-incompatible transplants, desensitisation. In the last decade, the frontier has moved to accepting donors who would once have been rejected on immunological grounds. ABO-incompatible transplants, HLA-incompatible transplants, and positive-crossmatch transplants are now performed in Indian tertiary centres with acceptable outcomes, using plasmapheresis or immunoadsorption to remove donor-specific antibodies, rituximab for B-cell depletion, IVIG for immunomodulation, and intensified induction and maintenance immunosuppression. What was surgically-forbidden in 2005 is now protocol-driven in 2025. India also runs paired-kidney-exchange programmes — the largest such Indian series has published outcomes matching or exceeding conventional single-pair outcomes — and, more recently, cross-organ exchanges (kidney-liver domino chains).⁵

Each of these expansions was made possible not just by surgical technique or organisational infrastructure, but by pharmacology that could handle the immunological complexity. Which brings us to the second shift.

3. The therapy — from a triple drug regimen to a full armamentarium

In the year 2000, a transplant patient’s chart in most Indian centres looked like this:

• Cyclosporine (calcineurin inhibitor)
• Azathioprine (antimetabolite) or early mycophenolate
• Prednisolone (corticosteroid)

The classic “triple drug regimen.” Powerful for its time. Toxic in ways we now design around.

The transplant patient’s chart in 2025 looks nothing like that. It is layered across four therapeutic conversations that did not exist as separate categories twenty-five years ago:

Induction. Before the transplanted organ ever meets the recipient’s immune system, we now condition that system with basiliximab (IL-2 receptor antagonist) or rabbit anti-thymocyte globulin (rATG). Induction has meaningfully reduced early acute rejection rates and enabled steroid-minimisation protocols that would have been unthinkable in the cyclosporine era.

Maintenance immunosuppression. Tacrolimus has largely displaced cyclosporine as the calcineurin-inhibitor backbone; mycophenolate mofetil and mycophenolate sodium (delayed-release) have replaced azathioprine as the standard antimetabolite. mTOR inhibitors — sirolimus, everolimus — occupy a growing role in patients with malignancy risk, chronic CNI nephrotoxicity, or specific paediatric indications. Steroids, when retained at all, are commonly reduced to physiological or sub-physiological maintenance doses.

Immune modulation for antibody-mediated risk. For the sensitised recipient, for the ABO-incompatible transplant, for desensitisation protocols: rituximab, plasmapheresis, IVIG, and in specialised centres, eculizumab and newer complement-pathway agents. Each of these deserves its own review; none of them existed as routine tools in 2000.

Infectious prophylaxis. This is the quietest revolution and, in outcome terms, one of the loudest. Valganciclovir for cytomegalovirus (CMV) prophylaxis over the first 100 – 200 post-transplant days has structurally changed how a transplant patient’s first year looks — from a period of near-inevitable CMV reactivation and hospitalisation to a period in which CMV is a manageable, monitored, largely-preventable event. Trimethoprim-sulfamethoxazole for Pneumocystis jirovecii. Fluconazole, isavuconazole, posaconazole for invasive fungal infection. Nucleoside analogues for hepatitis B in the HBV-positive donor or recipient. BK virus — once a poorly-understood cause of late graft loss — now monitored quantitatively with proactive immunosuppression reduction.

The Vyapitus transplant portfolio — CoverGraf® (Tacrolimus), Mycodapt-S™ (Mycophenolate Sodium delayed-release), and Valcurb® (Valganciclovir) — sits inside this evolution deliberately. These are not chosen because they are novel. They are chosen because they are what a competent Indian transplant team actually uses, every day, for the next thirty years of the recipient’s life. Continuity of supply on molecules like these is not a marketing claim. It is the therapy.

4. The economics — packages that used to sit under half a million now cross two million

When I entered this space, a kidney transplant in an Indian private tertiary hospital could be arranged at a package cost of approximately ₹3 – 5 lakh including surgery, in-hospital care, and initial immunosuppression. Liver and heart were higher, but the same order of magnitude.

Twenty-five years on, a kidney transplant package in a private centre typically ranges ₹8 – 15 lakh, and a liver or heart transplant package commonly ranges ₹18 – 25 lakh — with high-complexity, high-immunological-risk, or paediatric transplants running higher still. Independent international-patient pricing surveys corroborate this range (all-in kidney transplant packages for international patients quoted at USD 11,000 – 18,000, roughly ₹9 – 15 lakh at prevailing exchange).⁶

The economics shift is neither purely inflation nor purely provider margin. It is a real change in what the package now includes: induction therapy, extended CMV prophylaxis, molecular diagnostics for opportunistic infection surveillance, biopsy-driven protocol monitoring, therapeutic drug monitoring for tacrolimus troughs, and desensitisation protocols where required. A 2000-era package covered the transplant; a 2025-era package covers the first year of clinical decisions that determine whether the transplant survives.

This has three real consequences worth stating candidly:

1. Government schemes have had to expand. Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB PM-JAY) now covers renal transplantation at defined package rates in empanelled hospitals. State schemes — Maharashtra Public Health Scheme, Tamil Nadu CMCHIS, Rajasthan CMCHF and others — variously cover kidney and, in some cases, liver transplantation. The Pradhan Mantri National Dialysis Programme (PMNDP) is scaling in parallel to reduce bridge-to-transplant catastrophic spend.
2. Out-of-pocket spend is still substantial for the maintenance immunosuppression after the package is exhausted. A CoverGraf – Mycodapt-S – Valcurb regimen alone, plus the associated diagnostics, is a meaningful monthly cost for a family that has just borne the surgical package. Affordability of maintenance therapy — not the surgery itself — is now the primary determinant of long-term graft survival for economically-vulnerable recipients.
3. This is why molecular reliability and price stability of long-term immunosuppression matter more than the marketing of any single new drug. Indian generic immunosuppressants, produced under WHO-GMP-certified manufacturing, are typically priced at USD 100 – 250 per month — versus USD 1,500 – 3,000 per month for the same therapeutic exposure in the United States.⁶ Continuity is a clinical intervention.

5. The geography — Tier-2 and Tier-3 cities taking the lead

For most of my career, an Indian organ transplant meant travel: from the district town to a metro, from the metro to one of a small number of super-speciality quaternary centres in Chennai, Delhi, Mumbai, Bengaluru or Hyderabad. Post-transplant follow-up then required repeated return trips — each of which cost the family working days, lodging, and time away from local social support.

That map has changed. In the last decade, Tier-2 and, in select cases, Tier-3 city hospitals have established their own solid-organ transplant programmes — Nashik, Nagpur, Pune, Coimbatore, Kochi, Vijayawada, Indore, Lucknow, Chandigarh, Guwahati, Vishakhapatnam. Some are subsidiary units of the historic teaching institutions; many are independent private multi-speciality hospitals with local transplant surgical teams, in-house nephrology, and increasingly their own SOTTO-coordinated deceased-donor programmes. In August 2025 the Union Health Minister explicitly credited Tier-2 and Tier-3 city hospitals as a driver of the volume expansion.¹³

For a patient, geography compression is more than convenience. It is:

• Earlier presentation for evaluation, because the transplant work-up is now nearer to home
• Better adherence to the intensive first-year follow-up schedule
• Reduced total cost because travel, lodging and lost wages fall
• A more resilient long-term relationship with the transplant team, because the team is in the patient’s own city

There are still gaps. Many Tier-3 and rural populations remain effectively hours-to-days from the nearest transplant centre. But the trend is real and it is one of the strongest reasons to expect the 20,138 number to keep rising.

6. Awareness — and why the loss of public figures moved the needle

Public policy on organ donation moves slowly. Public attitude on organ donation moves in episodes, and unfortunately many of those episodes are triggered by grief.

The passing of Shri Vilasrao Deshmukh, former Chief Minister of Maharashtra, in August 2012, at the age of 67, from multi-organ failure while awaiting a liver transplant at a Chennai transplant centre, was one such episode. The public conversation that followed was clarifying: if a former CM with every conceivable form of access could not obtain a donor liver in time, the shortage of deceased organ donors in India was not a discretionary problem for the middle class — it was a national systemic one. Maharashtra’s deceased-donor programme accelerated in the years that followed, in part in his memory.

The story of Smt. Sushma Swaraj, the late Union Minister for External Affairs, is the mirror image. She received a kidney transplant in December 2016 — notably from an unrelated donor after her family was not a suitable immunological match. She returned to full public office and served with visible energy until her death in 2019. Her transplant, publicly acknowledged, normalised in a single stroke the ideas that (a) transplantation from unrelated donors is a legitimate, safe, life-restoring pathway; and (b) recipients can return to full high-functioning professional life. It is difficult to overstate what a story like that does for a family in a district town trying to decide whether their teenager should register for donation, or whether a father should accept a kidney from a family friend.

Neither of these was a policy document. Both moved policy.

The concerted awareness effort by the Ministry of Health & Family Welfare, the Directorate General of Health Services, NOTTO, the state SOTTOs, and a broad NGO ecosystem — MOHAN Foundation, Gift Your Organ Foundation, ORGAN India, the Organ Retrieval Banking Organisation network, the Zonal Transplant Coordination Committees in each metro, and countless hospital-linked donor family support groups — is the sustained effort that turned those episodic public moments into durable pledge growth. Indian Organ Donation Day, observed nationally on 3 August each year, sits at the centre of that calendar.

7. The world is now looking at India

There is a phase in the maturity of any national healthcare capability at which the country stops asking “how are others doing it?” and other countries start asking “how is India doing it?” That phase has arrived for solid-organ transplantation.

The reference facts are these. India’s 20,138 transplants in 2025 place it third globally — behind only the United States (~46,600 transplants in 2024) and China. India already leads the world in living-donor transplant volume.²⁴ The Lancet Regional Health Southeast Asia and international journals have begun to publish India-authored perspectives on paired-kidney-exchange, ABO-incompatible protocols, low-resource desensitisation, and cadaver-donor allocation modelling. Transplant surgeons trained in Chennai, Delhi and Hyderabad now visit Southeast Asian, African and Middle-Eastern programmes as invited faculty, not as students.

For the global waiting population — patients in countries where regulatory timelines, donor scarcity, or single-payer waitlists make transplantation a five-to-ten-year proposition — the Indian ecosystem now offers a credible answer. Countries whose end-stage patients would previously have deteriorated on the waitlist are now referring patients to Indian centres as a clinical decision, not just a cost decision. This is a status change in how the world reads Indian healthcare.

8. The medical value tourism inflow

The numbers on international patients coming to India for transplant care are now large and independently verified.

• 1,851 of the 18,378 transplants performed in India in 2023 were on foreign nationals — approximately 10 % of the national total, per NOTTO data cited in Outlook India’s medical-tourism analysis.⁷ Of these, 1,445 were performed in Delhi NCR.
• India granted 463,725 Medical Value Travel (MVT) visas in 2024 across all specialities — a substantial base of which is chronic and life-threatening care, including solid-organ transplantation.⁸⁹
• Independent 2024 industry estimates value India’s medical tourism market at approximately USD 7.69 billion, with roughly 7.3 million foreign patients visiting for treatment. Forward projections estimate the market at USD 8.7 billion in 2025 and USD 16.2 billion by 2030.⁷

The cost architecture explains the inflow more clearly than any brochure. A comprehensive kidney transplant in the United States is typically billed at USD 150,000 or more; the same procedure in a top Indian tertiary centre — pre-transplant work-up for donor and recipient included — falls in the range of USD 11,000 – 18,000.⁶ A liver transplant costing USD 500,000+ in the US ranges USD 30,000 – 50,000 in India.⁷ After a realistic USD 1,500 – 3,000 of travel, accommodation and visa costs, international patients still save 60 – 80 % on the surgical package alone.

Two points deserve emphasis:

1. The savings are not built on cheaper standards of care. They are built on lower structural costs of Indian healthcare: land, salaries, procurement, and the mature scale of Indian pharmaceutical manufacturing. The teams, the equipment, the protocols, and increasingly the accreditations (NABH, JCI) are internationally comparable. A patient at a top Indian transplant unit is being cared for by transplant surgeons and nephrologists with substantial international training and, in many cases, US or UK board certifications.
2. The post-transplant medication economics compound the savings. Because India manufactures the world’s largest generic immunosuppressant supply — Tacrolimus, Mycophenolate, Valganciclovir among many others — a lifelong post-transplant regimen that would cost USD 1,500 – 3,000 per month in the US costs USD 100 – 250 per month when supplied from India.⁶ For a patient facing thirty years of maintenance therapy, that arithmetic is decisive.

This inflow of international patients is a substantial contributor to the sustainability of Indian transplant infrastructure. It is also, done ethically and within the framework of THOTA and NOTTO’s foreign-patient protocols, a legitimate and increasingly important part of India’s soft-power healthcare footprint.

9. And yet — how far there is to go

A milestone brief that only celebrates is a dishonest brief. The internal disease burden that India carries in end-stage organ disease dwarfs everything the transplant system has so far achieved.

End-stage renal disease (ESRD). Peer-reviewed estimates place ESRD requiring transplantation at 151 – 232 per million population in India, translating to approximately 220,000 people currently requiring kidney transplantation. Chronic kidney disease affects approximately 17 % of the Indian population in aggregate.⁵ In 2022, more than two lakh patients required kidney transplants; only about 7,500 (approximately 3.4 %) received one.⁵ As of 27 July 2025, 73,646 patients were on the national kidney transplant waiting list, and more than 200 patients died while awaiting a kidney transplant in India in 2025 alone, with 132 of those deaths in Delhi — the highest of any single jurisdiction.¹⁰

End-stage liver disease (ESLD) and end-stage heart / lung failure carry a similarly wide demand-supply chasm. India’s annual liver transplant volume, while growing, remains a small fraction of the estimated annual liver-transplant need; heart and lung transplant programmes are concentrated in a smaller number of centres and constrained by cold-ischaemia logistics that India’s geography makes harder than most.

The blunt way to frame it: the country that just performed 20,138 transplants also lost more than 200 patients on the kidney waiting list in the same calendar year, and left over ninety-five per cent of its estimated annual kidney-transplant need unmet. The 20,138 figure is a genuine achievement. It is also nowhere near enough.

For a company that operates entirely in this therapy area, this is not a rhetorical framing. It is the daily working reality of every conversation with a transplant unit that is turning patients away for lack of a compatible organ, of every nephrology outpatient department where dialysis is being initiated as a bridge to a transplant that may not come, and of every family that has lost a member on the list.

10. The framework that must hold — how the next decade sustains this

The 20,138 milestone is a fragile achievement if the framework that produced it is not intentionally maintained. Four sustainability levers matter most:

10.1 Continued statutory and regulatory strengthening

The Transplantation of Human Organs and Tissues Act, 1994 and the 2014 Rules — with the amendments the Ministry has been progressively adopting — are the legal spine of the system. The remaining reform items include (a) further harmonising State-level Authorisation Committee processes so that unrelated-donor approvals are consistent across states, (b) extending the reach and independence of the National Organ Transplant Programme (NOTP) funding to underserved states, (c) deepening the digital pledge registry infrastructure so that the family’s decision at the moment of brainstem death is as low-friction as possible, and (d) modernising the rules governing paired-kidney-exchange and cross-organ exchanges to keep pace with clinical practice.

10.2 Building the workforce, not just the buildings

Transplantation is a team sport. Every new transplant centre requires nephrologists, transplant surgeons, transplant coordinators, immunologists, HLA and molecular diagnostic capacity, dialysis nurses, transplant pharmacists, dietitians, ICU capacity, and — critically — full-time Transplant Coordinators trained in the bereavement counselling that consented deceased-donor donation depends on. Workforce expansion in each of these roles is the rate-limiting step on the next doubling of the transplant number. Fellowships, structured training tracks, and public-private teaching partnerships need scaled investment.

10.3 Universalising affordability of maintenance therapy

The Indian generic pharmaceutical industry has already solved the price problem for the world. It has not yet, at scale, solved it for every Indian family with a graft recipient. Making WHO-GMP-standard maintenance immunosuppression — tacrolimus, mycophenolate, valganciclovir — reliably affordable and accessible in Tier-3 towns is a distributional and supply-chain challenge, not a manufacturing one. Vyapitus operates deliberately in this space; so do a small number of other focused Indian companies. The next expansion is not more molecules; it is deeper distribution of the molecules that already work.

10.4 Engaging more strata of society, and of administration

Awareness that penetrates only urban middle-class households produces a pledge base that scales but a donor base that doesn’t. The Ministry of Health & Family Welfare and the SOTTOs will need to work closely with State education departments, panchayat institutions, faith-based leaders, RTO / driving-licence authorities (for donor-registry integration), and the regional media in every state. The MOHAN Foundation, ORGAN India and Gift Your Organ Foundation are proven partners in this effort; the private sector — hospitals, insurers, employer wellness programmes and pharmaceutical companies including Vyapitus — has an obligation to fund and amplify the work rather than free-ride on it.

The denominator to sustaining this success is exactly what the user of every ecosystem knows: whatever produced this year’s number is what has to be renewed, refunded, retaught and re-committed to, every year, or the number will retreat.

11. Where Vyapitus sits in this landscape

Vyapitus Specialities was founded in 2018 on the conviction that a pharmaceutical company that does only nephrology, transplant, chronic kidney disease and renal nutrition — and does it with unbroken supply and consistent quality — would have a genuine role to play in the trajectory this brief has just described.

We are not a discovery-stage company. Our contribution is the everyday one that determines whether the transplant that a Tier-2 hospital just performed lasts thirty years or three. Our transplant portfolio — CoverGraf® (Tacrolimus), Mycodapt-S™ (Mycophenolate Sodium delayed-release), and Valcurb® (Valganciclovir) — is the working chest for the post-transplant year and the years after it. Our CKD, renal-nutrition, and hyperuricaemia ranges support the pre-transplant patient population from whose ranks the next 20,138 recipients will come.

The 2025 milestone is not our achievement. It belongs to the surgical teams, the transplant coordinators, the nephrologists, the immunologists, the intensivists, the transplant nurses, the families who donated, and above all the deceased donors and their families who chose grace in an unimaginable moment. Our job — and every pharmaceutical partner’s job — is to ensure that the medicines those recipients need are there, dependably, for the rest of their lives.

Twenty-five years in, that is the work I still find worth doing.

About the author

Caleb Masih is the Founder and Managing Director of Vyapitus Specialities Private Limited, a focused Indian super-speciality pharmaceutical company operating exclusively across nephrology, solid organ transplantation, chronic kidney disease management and renal nutrition. He serves concurrently as Executive Director on the board of LawCrust Global Consulting Ltd., a Public Limited Company incorporated in India (CIN U69100MH2023PLC413428, ROC Mumbai).

Caleb has spent over twenty-five years in leadership roles across the Indian pharmaceutical super-speciality sector, with particular depth in transplant immunosuppression, CKD-mineral & bone disorder therapeutics, and renal nutrition. His field perspective is grounded in sustained engagement with practicing nephrologists, transplant surgeons and hospital transplant programmes across India’s metro and Tier-2 city ecosystems.

The views expressed here are his own, in his capacity as Founder of Vyapitus Specialities, and are offered as a field practitioner’s reflection rather than as an academic evidence review.

Sources

Primary official sources:

News and analysis:

Peer-reviewed / clinical sources:

Independent industry pricing surveys:

Additional reference frameworks used throughout:

• NOTTO — National Organ and Tissue Transplant Organisation portal, notto.mohfw.gov.in, for the authoritative national allocation, statistics and pledge-registry data.
• Transplantation of Human Organs and Tissues Act, 1994 (as amended) and the Transplantation of Human Organs and Tissues Rules, 2014 — the statutory framework for related, unrelated, and deceased donation in India.
• MOHAN Foundation, ORGAN India, and Gift Your Organ Foundation — three of the largest civil-society organisations in the Indian organ-donation awareness ecosystem.
• Ministry of Corporate Affairs / MCA21 — company particulars for LAWCRUST GLOBAL CONSULTING LIMITED (CIN U69100MH2023PLC413428).

Disclaimers

This document is published by Vyapitus Specialities Private Limited as a Field Perspective, not as a scientific evidence review. The author’s own package-cost range observations from Indian tertiary centres are provided as professional context, and where directly quoted are cross-referenced to independent published pricing surveys (see ⁶, ⁷). Ranges vary substantially by hospital, city, insurance scheme and clinical complexity.

Molecular and procedural references are provided for context and are not prescribing recommendations. All Vyapitus brands mentioned — CoverGraf®, Mycodapt-S™, Valcurb® — are prescription medicines to be used solely under the direction of a registered medical practitioner and in accordance with their approved Indian product labels.

Names of the late Shri Vilasrao Deshmukh and the late Smt. Sushma Swaraj are used solely to acknowledge the public-awareness impact of their respective medical journeys; both are matters of public record.

References to LawCrust Global Consulting Limited (CIN U69100MH2023PLC413428) are informational in respect of the author’s directorship disclosure and do not imply any joint commercial position between Vyapitus Specialities Private Limited and LawCrust Global Consulting Limited.

Views expressed are those of the named author and do not represent the position of any other organisation with which he is associated.

See the project-level DISCLAIMER.md for the full medical, copyright, fair-use, and forward-looking-statement language.